MRK - NYSE

Merck & Co., Inc.

MRK·NYSE

$114.80

-0.36%

HealthcareDrug Manufacturers - General

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$283.54B

EPS7.3000

P/E Ratio15.73

Earnings Date08/04/2026

136.87B

Assets

17%

3Y+25.0%

5Y+49.0%

10Y+44.0%

84.20B

Total Liabilities

19%

3Y+33.0%

5Y+27.0%

10Y+53.0%

52.66B

Total Equity

14%

3Y+14.0%

5Y+107.0%

10Y+31.0%

Merck & Co., Inc. Funding & Solvency Profile

MRK · NYSE

Current Assets

Cash & Cash Equivalents14.56B

Net Receivables12.68B

Inventory6.66B

Other Current Assets9.49B

Total Current Assets44 B

Non-Current Assets

Property, Plant & Equipment26.82B

Goodwill & Intangible Assets48.26B

Long-Term Investments2.24B

Other Non-Current Assets16.03B

Total Non-Current Assets45 B

Total Assets

136.87B

Financial Health Analysis

Current Ratio

1.54x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

1.60x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

15 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

32% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Merck & Co., Inc. Balance Sheet

MRK • NYSE

Merck & Co., Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	14.6B	13.2B	6.8B	12.7B	8.1B	8.1B	9.7B	8B	6.1B	6.5B	8.5B	7.4B	15.6B	13.5B	13.5B	10.9B	9.3B	4.4B	5.3B	5.9B
Short-Term Investments	0.0	447M	252M	498M	0.0	0.0	774M	899M	2.4B	7.8B	4.9B	8.3B	1.9B	2.7B	1.4B	1.3B	293M	1.1B	2.9B	2.8B
Cash & Short-Term Investments	14.6B	13.7B	7.1B	13.2B	8.1B	8.1B	10.5B	8.9B	8.5B	14.3B	13.4B	15.7B	17.5B	16.1B	15B	12.2B	9.6B	5.5B	8.2B	8.7B
Net Receivables	12.7B	10.3B	10.3B	9.5B	9.2B	6.8B	6.8B	7.1B	6.9B	7B	6.5B	6.6B	7.2B	7.7B	8.3B	7.3B	6.6B	2.9B	3.6B	3.3B
Accounts Receivables	11.8B	10.3B	10.3B	9.5B	9.2B	6.8B	6.8B	7.1B	6.9B	7B	6.5B	6.6B	7.2B	7.7B	8.3B	7.3B	6.6B	2.9B	3.6B	3.3B
Other Receivables	904M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	6.7B	6.1B	6.4B	5.9B	6B	5.6B	6B	5.4B	5.1B	4.9B	4.7B	5.6B	6.2B	6.5B	6.3B	5.9B	8B	2.1B	1.9B	1.8B
Prepaids	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3B	1.4B
Other Current Assets	9.5B	8.7B	8.4B	7.2B	7B	7.4B	4.3B	4.5B	4.3B	4.4B	5.1B	4.7B	4.8B	4.5B	3.7B	3.7B	4.2B	8.6B	0.0	0.0
Total Current Assets	43.5B	38.8B	32.2B	35.7B	30.3B	27.8B	27.5B	25.9B	24.8B	30.6B	29.8B	32.6B	35.7B	34.9B	33.2B	29.1B	28.4B	19.1B	15B	15.2B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	26.8B	23.8B	23.1B	21.4B	19.3B	17B	15.1B	13.3B	12.4B	12B	12.5B	13.1B	15B	16B	16.3B	17.1B	18.3B	12B	12.3B	13.2B
Goodwill	21.6B	21.7B	21.2B	21.2B	21.3B	18.9B	19.4B	18.3B	18.3B	18.2B	17.7B	13B	12.3B	12.1B	12.2B	12.4B	12B	1.4B	1.5B	1.4B
Intangible Assets	26.7B	16.4B	18B	20.3B	22.9B	14.1B	14.2B	13.1B	14.2B	17.3B	22.6B	20.4B	23.8B	29.1B	34.3B	39.5B	47.8B	525.4M	713.2M	943.9M
Goodwill & Intangible Assets	48.3B	38B	39.2B	41.5B	44.2B	33B	33.6B	31.4B	32.5B	35.5B	40.3B	33.4B	36.1B	41.2B	46.5B	51.8B	59.8B	2B	2.2B	2.4B
Long-Term Investments	2.2B	463M	252M	1B	370M	785M	1.5B	6.2B	12.1B	11.4B	13B	13.5B	9.8B	7.3B	3.5B	2.2B	432M	6.5B	0.0	0.0
Other Non-Current Assets	16B	16B	12B	9.5B	11.6B	13.1B	6.8B	5.9B	6.1B	5.9B	6.1B	5.5B	9.1B	6.7B	5.7B	5.6B	5.4B	7.6B	18.8B	13.8B
Total Non-Current Assets	93.4B	78.3B	74.5B	73.4B	75.4B	63.8B	56.9B	56.8B	63.1B	64.8B	71.9B	65.6B	70B	71.3B	71.9B	76.7B	83.9B	28.1B	33.3B	29.3B
Total Assets	136.9B	117.1B	106.7B	109.2B	105.7B	91.6B	84.4B	82.6B	87.9B	95.4B	101.7B	98.2B	105.6B	106.1B	105.1B	105.8B	112.3B	47.2B	48.4B	44.6B
LIABILITIES
CURRENT LIABILITIES
Total Payables	11.3B	10.1B	8.6B	8.1B	7.6B	7.6B	6.1B	6.7B	5.1B	6.4B	5.4B	5.2B	3.8B	4.3B	4.1B	4.7B	4.6B	2.8B	624.5M	496.6M
Accounts Payable	4.4B	4.1B	3.9B	4.3B	4.6B	4.3B	3.7B	3.3B	3.1B	2.8B	2.5B	2.6B	2.3B	1.8B	2B	2.3B	2.2B	617.6M	624.5M	496.6M
Other Payables	6.9B	6B	4.6B	3.9B	3B	3.3B	2.3B	3.4B	2B	3.6B	2.9B	2.5B	1.6B	2.5B	2.1B	2.4B	2.4B	2.2B	0.0	0.0
Accrued Expenses	85M	15.7B	15.8B	14.2B	13.9B	12.2B	12.5B	10.2B	10.4B	10.3B	11.2B	10.5B	9.5B	9.7B	10.2B	8.5B	9.5B	9.2B	8.5B	6.7B
Short Term Debt	2.9B	2.6B	1.4B	1.9B	2.4B	6.4B	3.6B	5.3B	3.1B	568M	2.6B	2.7B	4.5B	4.3B	2B	2.4B	1.4B	2.3B	1.8B	1.3B
Capital Lease Obligations (Current)	0.0	282M	285M	281M	304M	291M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	3.9B	2.6B	2B	1.2B	1.6B	736M	2B	708M	2.2B	1.6B	1.6B	251M	1.2B	781M	1.2B	1.3B	183M	617M	323M
Other Current Liabilities	14.1B	-282M	-285M	-281M	-304M	795M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	207M	0.0	1.3B	4.3B
Total Current Liabilities	28.3B	28.4B	25.7B	24.2B	23.9B	27.3B	22.2B	22.2B	18.6B	17.2B	19.2B	18.4B	17.9B	18.3B	16.2B	15.6B	15.6B	14.3B	12.3B	12.7B
NON-CURRENT LIABILITIES
Long Term Debt	46.8B	34.5B	33.7B	28.7B	30.7B	25.4B	22.7B	19.8B	21.4B	24.3B	23.8B	18.7B	20.5B	16.3B	15.5B	15.5B	16.1B	3.9B	3.9B	5.6B
Deferred Tax Liabilities (Non-Current)	1.4B	1.4B	871M	1.8B	3.4B	1B	1.5B	1.7B	2.2B	5.1B	6.5B	4.5B	6.8B	5.7B	16.4B	17.9B	19.1B	7.8B	11.6B	6.3B
Other Non-Current Liabilities	6.8B	5.6B	7.9B	7.3B	8.2B	11.2B	11.2B	12B	11.1B	8.5B	7.3B	7.8B	8.1B	10.3B	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	55.9B	42.3B	43.3B	38.9B	43.6B	38.9B	36.2B	33.5B	34.7B	37.9B	37.7B	31B	35.5B	32.3B	31.9B	33.3B	35.2B	11.7B	15.5B	11.9B
Capital Lease Obligations	901M	1.2B	1.2B	1.3B	1.5B	1.6B	768M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	84.2B	70.7B	69B	63.1B	67.4B	66.2B	58.4B	55.8B	53.3B	55.1B	56.9B	49.4B	53.3B	50.7B	48.2B	49B	50.8B	26B	27.8B	24.6B
SHAREHOLDERS' EQUITY
Treasury Stock	-63B	-58.3B	-57.5B	-56.5B	-57.1B	-56.8B	-56B	-50.9B	-43.8B	-40.5B	-38.5B	-35.3B	-29.6B	-24.7B	-23.8B	-22.4B	-21B	-30.7B	-28.2B	-27.6B
Common Stock	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	1.8B	29.8M	29.8M	29.8M
Additional Paid-In Capital	45B	44.7B	44.5B	44.4B	44.2B	39.6B	39.7B	38.8B	39.9B	39.9B	40.2B	40.4B	40.5B	40.6B	40.7B	40.7B	39.7B	8.3B	8B	7.2B
Retained Earnings	73.1B	63.1B	53.9B	61.1B	53.7B	47.4B	46.6B	42.6B	41.4B	44.1B	45.3B	46B	39.3B	40B	39B	37.5B	41.4B	43.7B	39.1B	39.1B
Accumulated Other Comprehensive Income/Loss	-4.3B	-4.9B	-5.2B	-4.8B	-4.4B	-6.6B	-6.2B	-5.5B	-4.9B	-5.2B	-4.1B	-4.3B	-2.2B	-4.7B	-3.1B	-3.2B	-2.8B	-2.6B	-826.1M	-1.2B
Total Stockholders' Equity	52.6B	46.3B	37.6B	46B	38.2B	25.3B	25.9B	26.7B	34.3B	40.1B	44.7B	48.6B	49.8B	53B	54.5B	54.4B	59.1B	18.8B	18.2B	17.6B
Total Equity	52.7B	46.4B	37.6B	46.1B	38.3B	25.4B	26B	26.9B	34.6B	40.3B	44.8B	48.8B	52.3B	55.5B	56.9B	56.8B	61.5B	21.2B	20.6B	20B
Minority Interest	56M	59M	54M	67M	73M	87M	94M	181M	233M	220M	91M	144M	2.6B	2.4B	2.4B	2.4B	2.4B	2.4B	2.4B	2.4B
SUMMARY
Total Liabilities & Equity	136.9B	117.1B	106.7B	109.2B	105.7B	91.6B	84.4B	82.6B	87.9B	95.4B	101.7B	98.2B	105.6B	106.1B	105.1B	105.8B	112.3B	47.2B	48.4B	44.6B
Total Investments	2.2B	910M	504M	1.5B	370M	785M	2.2B	7.1B	14.5B	19.2B	17.9B	21.8B	11.6B	10B	4.9B	3.5B	725M	7.6B	2.9B	2.8B
Total Debt	50.5B	38.3B	36.3B	32B	34.6B	33.4B	27.4B	25.1B	24.4B	24.8B	26.4B	21.4B	25.1B	20.6B	17.5B	17.9B	17.5B	6.2B	5.7B	6.8B
Net Debt	36B	25B	29.4B	19.3B	26.5B	25.4B	17.7B	17.1B	18.3B	18.3B	17.9B	14B	9.4B	7.1B	4B	7B	8.2B	1.9B	403.3M	921.4M
Shares Outstanding	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734	2,513,204,734

SEC Filings

MRK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 28, 2026	May 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 22, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 08, 2026	May 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 03, 2026	February 03, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 30, 2025	2025	View Filing

Showing 1 to 10 of 463 filings

Related Guides

Blog Categories

Continue your MRK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.